상세 보기
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
- Kalinsky, Kevin;
- Bianchini, Giampaolo;
- Hamilton, Erika P.;
- Graff, Stephanie L.;
- Park, Kyong Hwa;
- 외 15명
Citations
WEB OF SCIENCE
52- 제목
- Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
- 저자
- Kalinsky, Kevin; Bianchini, Giampaolo; Hamilton, Erika P.; Graff, Stephanie L.; Park, Kyong Hwa; Jeselsohn, Rinath; Demirci, Umut; Martin, Miguel; Layman, Rachel M.; Hurvitz, Sara A.; Sammons, Sarah L.; Kaufman, Peter A.; Munoz, Montserrat; Tseng, Ling-Ming; Knoderer, Holly; Nguyen, Bastien; Zhou, Yanhong; Ravenberg, Elizabeth; Litchfield, Lacey M.; Wander, Seth Andrew
- 발행일
- 2024-06-10
- 유형
- Meeting Abstract
- 권
- 42
- 호
- 17_SUPPL
- 페이지
- LBA1001 ~ LBA1001